Qiagen N.V. (NYSE:QGEN - Get Free Report) has earned a consensus recommendation of "Hold" from the fourteen analysts that are currently covering the company, MarketBeat reports. Nine equities research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $43.9250.
A number of equities research analysts have commented on the company. Citigroup reissued a "neutral" rating and issued a $45.00 price objective (up from $38.00) on shares of Qiagen in a research note on Monday, August 10th. Morgan Stanley raised shares of Qiagen from an "overweight" rating to an "overweight" rating and lifted their price target for the company from $40.00 to $42.00 in a research report on Tuesday, June 23rd. Stifel Nicolaus set a $40.00 price target on shares of Qiagen in a research note on Friday, August 7th. TD Cowen restated a "hold" rating on shares of Qiagen in a report on Wednesday, July 15th. Finally, Kepler Capital Markets set a $38.60 price objective on shares of Qiagen and gave the company a "hold" rating in a research note on Thursday, June 25th.
Check Out Our Latest Analysis on Qiagen
Qiagen Price Performance
Shares of QGEN opened at $43.35 on Tuesday. The business has a 50-day moving average of $41.51 and a 200-day moving average of $40.54. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31. The company has a market capitalization of $8.93 billion, a price-to-earnings ratio of 22.21, a price-to-earnings-growth ratio of 4.29 and a beta of 0.63. Qiagen has a 1 year low of $32.53 and a 1 year high of $57.81.
Qiagen (NYSE:QGEN - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, topping analysts' consensus estimates of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The business had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. During the same quarter last year, the firm earned $0.60 earnings per share. Qiagen's quarterly revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, equities research analysts anticipate that Qiagen will post 2.43 earnings per share for the current year.
Institutional Investors Weigh In On Qiagen
Institutional investors and hedge funds have recently bought and sold shares of the stock. Banque Cantonale Vaudoise lifted its stake in Qiagen by 1.8% during the 4th quarter. Banque Cantonale Vaudoise now owns 16,363 shares of the company's stock valued at $747,000 after acquiring an additional 290 shares in the last quarter. Commerce Bank lifted its position in shares of Qiagen by 4.9% during the fourth quarter. Commerce Bank now owns 6,725 shares of the company's stock valued at $302,000 after purchasing an additional 314 shares in the last quarter. Truist Financial Corp lifted its position in shares of Qiagen by 4.1% during the fourth quarter. Truist Financial Corp now owns 8,421 shares of the company's stock valued at $379,000 after purchasing an additional 331 shares in the last quarter. Private Advisor Group LLC boosted its holdings in Qiagen by 7.1% during the third quarter. Private Advisor Group LLC now owns 5,730 shares of the company's stock worth $256,000 after purchasing an additional 378 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in Qiagen by 45.6% during the fourth quarter. Farther Finance Advisors LLC now owns 1,730 shares of the company's stock worth $78,000 after purchasing an additional 542 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.
About Qiagen
(
Get Free Report)
Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.
The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
